Aytu Biopharma, Inc.
AYTU
$2.17
-$0.04-1.81%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.84% | -19.04% | -31.79% | -34.46% | -39.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.84% | -19.04% | -31.79% | -34.46% | -39.31% |
| Cost of Revenue | 27.42% | -22.40% | -44.57% | -55.63% | -60.44% |
| Gross Profit | -6.57% | -17.57% | -25.05% | -22.12% | -26.38% |
| SG&A Expenses | -8.93% | -15.90% | -28.93% | -37.83% | -40.01% |
| Depreciation & Amortization | 0.00% | -6.92% | -13.03% | -18.49% | -23.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.20% | -17.12% | -32.45% | -42.57% | -46.03% |
| Operating Income | 349.03% | -58.88% | 46.76% | 111.14% | 104.58% |
| Income Before Tax | -32.44% | 130.70% | 84.59% | 94.09% | 39.14% |
| Income Tax Expenses | -79.60% | -35.36% | 90.26% | -- | -- |
| Earnings from Continuing Operations | -13.27% | 120.00% | 76.33% | 83.40% | 26.57% |
| Earnings from Discontinued Operations | 118.65% | 67.34% | 10.23% | -254.87% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.40% | 111.98% | 70.87% | 74.46% | 7.08% |
| EBIT | 349.03% | -58.88% | 46.76% | 111.14% | 104.58% |
| EBITDA | 8.56% | -34.86% | -3.18% | 338.39% | 307.46% |
| EPS Basic | 33.83% | 107.62% | 75.98% | 81.48% | 42.19% |
| Normalized Basic EPS | 73.33% | 194.74% | 111.66% | 107.36% | 61.31% |
| EPS Diluted | -9.26% | 60.74% | 56.43% | 74.94% | 42.15% |
| Normalized Diluted EPS | 47.49% | 167.93% | 105.33% | 104.72% | 61.31% |
| Average Basic Shares Outstanding | 13.42% | 15.85% | 23.76% | 38.12% | 64.11% |
| Average Diluted Shares Outstanding | 47.07% | 51.90% | 52.29% | 56.53% | 64.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |